Therapeutics News

Dermatitis refers to various inflammations of the skin that occur in both children and adults. Some symptoms of dermatitis may overlap. The inflammation can be atopic, contact or seborrheic in nature but can also include mild conditions such as dandruff.

The two compendia that Medicare Part D recognizes to make coverage determinations for off-label prescribing were “incomplete, outdated, idiosyncratic, and unpredictable” for some chronic dermatologic conditions, according to findings recently published in JAMA Dermatology.

In 2018, after President Donald Trump publicly condemned the pharmaceutical industry for skyrocketing prescription drug prices, several of the largest drug manufacturers — including Merck, Novartis, Pfizer and Roche — announced a series of temporary price freezes to their brand-name medications.

CHICAGO — Bimekizumab, a monoclonal antibody that neutralizes both IL-17A and IL-17F, significantly improved both musculoskeletal and skin outcomes among patients with active psoriatic arthritis, according to phase 2b data presented at the ACR/ARHP 2018 Annual Meeting.

Acupuncture was one of several complementary and alternative therapies that benefited patients with psoriasis, according to a systematic review recently published in JAMA Dermatology.

The FDA has approved 75 mg/0.5 mL and 150 mg/1 mL single-dose prefilled syringes of Xolair as additional formulations for patients with allergic asthma and chronic idiopathic urticaria, according to press releases from Genentech and Novartis.

The FDA has granted orphan drug designation to lenabasum for the treatment of dermatomyositis, a systemic autoimmune condition characterized by skin and muscle involvement, according to a press release from Corbus Pharmaceuticals.

The FDA has approved an oral formulation of TPOXX for the treatment of smallpox, citing concerns that the infectious disease, long considered eradicated since 1980, could potentially be used as a bioweapon, according to a press release.

The FDA has withdrawn a draft guidance intended to provide advice for biosimilar sponsors regarding the determination of similarity between the biosimilar and its reference product, following public comments raising questions about its effects on biosimilar development, according to a press release.

The FDA has approved rituximab for the treatment of adult patients with moderate-to-severe pemphigus vulgaris, a rare autoimmune blistering disease that affects the skin and mucous membranes, according to a company press release.